Rationale and therapeutic basis for patients receiving recombinant interleukin-2.
Dudjak
L A
LA
Medical Division, University of Pittsburgh Medical Center, PA 15213.
D006728:Hormones / Q000378:metabolism; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects; D008222:Lymphokines / Q000096:biosynthesis; D009369:Neoplasms / Q000628:therapy; D015375:Receptors, Interleukin-2 / Q000187:drug effects / Q000502:physiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects
D006728:Hormones; D007376:Interleukin-2; D008222:Lymphokines; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins